File name
Scottish Cancer Registry Smr06 Variables
Return to search
.PDF
Scottish Cancer Registry (SMR06)
Description
Public Health Scotland is responsible for the collection of information on Scottish residents when they are diagnosed with malignant (and some benign) tumours.
Related tags
Technical information
A JSON file is available with further technical information. This can include details of variables and data classes contained in the dataset.
Preview of JSON file
{
"required": {
"gatewayId": "79",
"gatewayPid": "01ba5dd7-201e-4006-bc92-9665a8f0f698",
"issued": "2024-10-08T11:28:20.471Z",
"modified": "2024-10-08T11:28:20.471Z",
"version": "10.0.0",
"revisions": [
{
"version": "1.0.0",
"url": "https://web.prod.hdruk.cloud//dataset/79?version=1.0.0"
}
]
},
"summary": {
"abstract": "Public Health Scotland is responsible for the collection of information on Scottish residents when they are diagnosed with malignant (and some benign) tumours.",
"contactPoint": "phs.edris@phs.scot",
"keywords": "Cancer",
"datasetType": "Health and disease",
"datasetSubType": "Not applicable",
"populationSize": -1,
"description": "The registry began in 1958 collecting personal, demographic and diagnosis information (such as site, histology, behaviour, histological confirmation and hospital of diagnosis) from cancer patients. In 1997, a new electronic cancer recording system was launched and at this point the registry was extended to include extra information on tumour stage (for breast, cervical and colorectal cancer), tumour grade and treatment information. A wide variety of geographical data is also included in the dataset including Scottish Index of Multiple Deprivation and Carstairs measures, census output area, NHS Board, Electoral Ward and Parliamentary constituency.",
"shortTitle": "Scottish Cancer Registry (SMR06)",
"title": "Scottish Cancer Registry (SMR06)",
"publisher": {
"name": "Public Health Scotland",
"gatewayId": "07"
},
"inPipeline": "Not available"
},
"coverage": {
"spatial": "United Kingdom,Scotland",
"typicalAgeRange": "0-150"
},
"provenance": {
"origin": {
"imageContrast": "Not stated"
},
"temporal": {
"startDate": "1981-01-01T00:00:00Z",
"timeLag": "More than 6 months",
"accrualPeriodicity": "Annual",
"distributionReleaseDate": "2020-08-31T23:00:00Z"
}
},
"accessibility": {
"access": {
"deliveryLeadTime": "Not applicable",
"jurisdiction": "GB-GBN",
"dataController": "Public Health Scotland",
"dataProcessor": "National Services Scotland",
"accessRights": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/services-we-offer/",
"accessService": "Scottish National Safe Haven / Trusted Research Environment: https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/national-safe-haven-nsh/",
"accessRequestCost": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/cost-of-services/",
"accessServiceCategory": "TRE/SDE"
},
"usage": {
"resourceCreator": {
"name": "National Services Scotland"
}
},
"formatAndStandards": {
"vocabularyEncodingSchemes": "NHS SCOTLAND NATIONAL CODES",
"languages": "en",
"formats": "text/csv"
}
},
"linkage": {
"associatedMedia": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/overview/what-is-edris/;,;https://www.researchdata.scot/media/gz1lpmk2/scottish-cancer-registry-smr06-variables.pdf"
},
"observations": [
{
"observedNode": "Events",
"measuredValue": 1090594,
"observationDate": "2021-01-16T00:00:00Z",
"measuredProperty": "count",
"disambiguatingDescription": "Episodes"
}
],
"structuralMetadata": [
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First \nHormone Therapy",
"dataType": "8",
"sensitive": false,
"description": "Date of first Hormone Therapy DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of First \nHormone \nTherapy",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP practice initiating Hormone Therapy (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of First Radical Surgery",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP practice where a surgical treatment was first carried out (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of First Chemotherapy",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP practice of first Chemotherapy (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with hormone therapy",
"dataType": "1",
"sensitive": false,
"description": "Indicates if patient has had Hormone treatment. Hormone therapy is the use of hormones to treat cancer. Hormones are 'chemical messengers' released by the organs and dispersed by the blood to produce effects on target organs e.g. oestrogens. Most likely to apply to Breast, Prostate, Endometrial (uterus) and to a lesser extent, hypernephroma of kidney. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of First Radiotherapy",
"dataType": "5",
"sensitive": false,
"description": "Institution code of Hospital where Radiotherapy was first carried out (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with other therapy",
"dataType": "1",
"sensitive": false,
"description": "Other Therapy. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with Radiotherapy",
"dataType": "1",
"sensitive": false,
"description": "Indicates if patient has been treated with radiotherapy. Radiotherapy is either external beam, or the radioactive source can be introduced directly into the patient’s body. Radiotherapy may be used for: curative treatment e.g. early seminomas, palliative treatment to contain the tumour & control symptoms e.g. metastatic breast cancer, in combination with other curative treatments e.g. for tumours of the cervix, and to sites other than the primary or metastases e.g. organ ablation or prophylaxis. \nOptions: \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of First \n(Palliative) Surgery",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP practice where a surgical treatment was first carried out (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Type of radiotherapy",
"dataType": "1",
"sensitive": false,
"description": "Type of radiotherapy administered collected from 01.01.2016. Options: \nCode \tDescription \n1 \tBrachytherapy \n2 \tExternal beam/Teletherapy \n3 \tProton beam therapy \n\t4 \t \tRadioisotope therapy \n9 \tNot Known"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP Practice \nof First \nBiological/Immun otherapy",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP practice initiating Hormone Therapy (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Entered into \nClinical Trial",
"dataType": "1",
"sensitive": false,
"description": "Formerly Treatment Protocol Used This indicates whether the patient has been recruited into a specific clinical trial. Only use the Not Known option if you feel you do not have an adequate set of medical records on which to base your assessment. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First \n(Palliative) Surgery",
"dataType": "8",
"sensitive": false,
"description": "Date of first radical surgical treatment DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First Radical Surgery",
"dataType": "8",
"sensitive": false,
"description": "Date of first radical surgical treatment DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First Chemotherapy",
"dataType": "8",
"sensitive": false,
"description": "Date of first Chemotherapy DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with \nPalliative Surgery",
"dataType": "1",
"sensitive": false,
"description": "Palliative Surgery -there are 4 options for this treatment field: \nCode \tDescription \n0 \tNo - no palliative surgery \n1 \tYes – to relieve the effects of the tumour but not to remove the tumour e.g. stent/shunt \n7 \tPlanned – palliative surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned palliative surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2016"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First \nBiological/Immun otherapy",
"dataType": "8",
"sensitive": false,
"description": "Date of first Hormone Therapy DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Referred to Oncologist",
"dataType": "1",
"sensitive": false,
"description": "Referred to a Clinical Oncologist (Radiotherapist) or Medical Oncologist. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned to refer \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital / GP of diagnosis",
"dataType": "5",
"sensitive": false,
"description": "Hospital of diagnosis denotes the location (institution) code of the hospital in which the diagnosis was first made. This may also be a GP surgery code if an initial biopsy was taken by a GP. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997. For registrations with a Scottish incidence date up to 31.12.1996, see Old Hosp Code field on Stats screen."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Type of other therapy",
"dataType": "2",
"sensitive": false,
"description": "Indicates the type of Other Therapy treatment carried out. Options: \nCode \tDescription \n1 \tAnagrelide \n2 \tAnti-Helicobacter/H.pylori treatment/eradication therapy \n3 \tBisphosphonate \n\t4 \t \tBotox injection \n5 \tCorticosteroids \n6 \tDopamine agonist therapy \n7 \tHelmet/Electric Helmet \n8 \tHyperbaric oxygen therapy \n9 \tSupportive Care/Best Supportive Care \n10 \tVenesection \n11 \tNo longer in use (Watchful Wait - See option 13) \n12 \tEmbolisation \n13 \tActive Surveillance/Watchful Wait \n14 \tNot Known \n15 \tPhotopheresis \n \nThis field was previously text only and was collected for all registrations with a Scottish incidence date from 1.1.1997. \nThis field changed to a dropdown option for registrations from 1.1.2016"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Hospital/GP \nPractice of Other Therapy",
"dataType": "5",
"sensitive": false,
"description": "Institution code/practice code of Hospital/GP surgery where Other Therapy was first carried out (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "No Treatment Reason",
"dataType": "2",
"sensitive": false,
"description": "This is the reason why no treatment has taken place. It applies to all registerable cancers with a Scottish incidence date from 1.1.2017. This is only to be completed if no treatment has taken place. \n \n \nOptions: \n0 \tDied before treatment was given \n1 \tRefused treatment \n2 \tAsymptomatic \n3 \tDeath Certificate only \n4 \tPost-mortem only \n5 \tUnfit to treat: significant co-morbidity and/or advanced cancer \n6 \tNo record of treatment \n7 \tOther \n8 \tUnknown primary site \n9 \tNo active treatment available \n10 \tNot Known"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Radiotherapy to \nMetastases",
"dataType": "1",
"sensitive": false,
"description": "Radiotherapy treatment to Metastases. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Radiotherapy Other",
"dataType": "1",
"sensitive": false,
"description": "Radiotherapy treatment to Other (such as organ ablation or prophylaxis). Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Radiotherapy to \nPrimary",
"dataType": "1",
"sensitive": false,
"description": "Radiotherapy treatment to Primary site. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with Chemotherapy",
"dataType": "1",
"sensitive": false,
"description": "Indicates if patient has had Systemic chemotherapy treatment. \nChemotherapy literally means treatment with drugs but is conventionally used to describe the use of chemical agents to treat cancer. These agents may be used alone, or in conjunction with surgery and/or radiotherapy. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Therapy \nObjectives",
"dataType": "1",
"sensitive": false,
"description": "Intent is most likely to be curative in early stage of disease e.g. microinvasive, or non invasive, in situ disease, T1 or T2 N0 M0 , node negative breast cancer, Dukes’ A colorectal cancer, FIGO I cervical cancer. Intent unlikely to be curative in advanced disease e.g. M1 breast cancer, Dukes’ D, FIGO IV. \n \nOptions: \nCode \tDescription \n1 \tCurative intent \n2 \tNon-curative intent (Palliative) \n9 \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First Other Therapy",
"dataType": "8",
"sensitive": false,
"description": "Date of first Other Therapy DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with Surgery",
"dataType": "1",
"sensitive": false,
"description": "Surgery -there are 4 options for this treatment field: \nCode \tDescription \n0 \tNo - no surgery OR exploratory surgery only with or without diagnostic biopsy [e.g. diagnostic laparotomy with or without incisional biopsy (‘open and close’), needle biopsy, and diagnostic endoscopy with or without incisional biopsy \n1 \tYes - partial or total resection of primary and/or metastases (including endoscopic resection or biopsy where there is intent to remove all or bulk of macroscopic neoplastic tissue, e.g., excision biopsy or cone biopsy). Surgery should also include palliative procedures e.g. to bypass obstructive lesions or surgical procedures intended to manipulate hormone levels e.g. by the removal of ovaries or testicles \n7 \tPlanned - surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997 - 31.12.2015 incidence \n."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with \nRadical Surgery",
"dataType": "1",
"sensitive": false,
"description": "Radical Surgery -there are 4 options for this treatment field: \nCode \tDescription \n0 \tNo - no radical surgery \n1 \tYes – removal, part removal or destruction of the primary tumour e.g. excision, resection or laser treatment. It may also include resection of metastasis \n7 \tPlanned – radical surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned radical surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2016 \n."
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Date of First Radiotherapy",
"dataType": "1",
"sensitive": false,
"description": "Date of first Radiotherapy treatment DD-MMM-YYYY (if applicable)"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "INITIAL TREATMENT",
"columns": [
{
"name": "Treated with Biological/Immun otherapy",
"dataType": "1",
"sensitive": false,
"description": "Indicates if patient has had Biological/Immunotherapy. Biological therapies are treatments that act on processes in cells. They may: stop cancer cells from dividing and growing; seek out cancer cells and kill them; encourage the immune system to attack cancer cells. There are many different types of biological therapies including immunotherapy. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997"
}
],
"description": "INITIAL TREATMENT (TUMOUR LEVEL)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO StageAfter Surgery (Ovary only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage before surgery. Options are the same for before or after surgery"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "Before Surgery (Peritoneum)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the Peritoneum (ICD10 C48*) with an incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage after surgery. Options are the same for before or after surgery \n \n \nCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s) \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings \n1c \tTumour involves 1 or both ovaries or fallopian tubes \n1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n3a1 \tPositive retroperitoneal lymph nodes only \n3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement \n3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n4 \tDistant metastasis excluding peritoneal metastasis \n4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) \n9 \tNot known"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO Stage – Before Surgery (Cervix only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. FIGO stage has been collected for malignant tumours of the cervix (ICD10 C53*) with a Scottish incidence date from 1.1.1997 onwards. \nThis is a new field to record stage before surgery if possible, and will be collected for all malignant tumours of the cervix (C53*) from 1.1.2005. \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nOptions for cervix: \nCode \tDescription \n1 \tTumour strictly confined to cervix (extension to the corpus uteri should be disregarded) \n2 \tTumour extends beyond the cervix/uterus but not as far as pelvic wall or lower third of the vagina \n3 \tTumour extends to the pelvic wall or lower third of the vagina (includes all cases with hydronephrosis or non-functioning kidney or both) \n4 \tTumour has invaded or spread beyond the true pelvis, bone, or has clinically involved the mucosa (lining) of the bladder or rectum (bullous oedema as such does not permit a case to be allotted to stage IV) \n9 \tNot Known \nFIGO Stage classification change and from 1.1.2014. See also FIGO stage after surgery. Options are the same for before or after surgery. Options: \nCode \tDescription \n1 \tThe carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded). \n1a \tInvasive carcinoma which can be diagnosed only by microscopy. All macroscopically visible lesions - even with superficial invasion - are allotted to Stage Ib carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and horizontal extension of not > 7.0 mm. Depth of invasion should not be > 5.0 mm taken from the base of the epithelium of the original tissue - superficial or glandular. The involvement of vascular spaces should not change the stage allotment. \n1a1 \tMeasured stromal invasion of not > 3.0 mm in depth and extension of not > 7.0 mm. \n1a2 \tMeasured stromal invasion of > 3.0 mm and not > 5.0 mm with an extension of not > 7.0 mm. \n1b \tClinically visible lesions limited to the cervix uteri or preclinical cancers greater than Stage IA. \n1b1 \tClinically visible lesions not > 4.0 cm. \n1b2 \tClinically visible lesions > 4.0 cm. \n2 \tCervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. \n2a \tNo obvious parametrial involvement. \n2a1 \tClinically visible lesion <=4.0 cm in greatest dimension \n2a2 \tClinically visible lesion >4.0 cm in greatest dimension \n2b \tObvious parametrial involvement. \n3 \tThe carcinoma has extended to the pelvic wall. On rectal examination, there is no cancer-free space between the tumour and the pelvic wall. The tumour involves the lower-third of the vagina. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to other causes. \n3a \tTumour involves lower-third of the vagina, with no extension to the pelvic wall. \n3b \tExtension to the pelvic wall and/or hydronephrosis or non-functioning kidney \n4 \tThe carcinoma has extended beyond the true pelvis, or has involved (biopsy-proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV. \n4a \tSpread of the growth to adjacent organs. \n4b \tSpread to distant organs. \n9 \tNot known"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO StageAfter Surgery (Corpus Uteri only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the Corpus Uteri (ICD10 C54*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage before surgery. Options are the same for before or after surgery"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "Dukes’ Stage (Colorectal only)",
"dataType": "2",
"sensitive": false,
"description": "Stage (Colorectal) indicates the extent of spread of the invasive tumour at diagnosis in terms of the pathological and/or clinical findings for Socrates. Extent of Primary tumour for Colorectal cancer - \nDukes’ staging is primarily based on histological findings. Dukes’ Staging Classification Options: \n \nCode \tDescription \nA \tTumour limited to muscularis propria (muscle coat), regional lymph nodes negative \nB \tTumour invades through muscularis propria into serosa/subserosa or through peritoneum but regional lymph nodes negative \nC1 \tRegional lymph nodes positive but apical node negative \nC2 \tRegional lymph nodes positive, apical lymph node positive \nD \tDistant metastases (e.g. liver) \n9 \tNot Known \nNote: Dukes’ stage D was not included in the original Dukes’ classification \nNote: Regional lymph nodes are the pericolic and perirectal and those located along the ileocolic, right colic, middle colic, left colic, inferior mesenteric and superior rectal (haemorrhoidal) arteries \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997 onwards for all malignant colorectal (ICD10 C18 – C20) and anal (ICD10 C21) tumours."
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO Stage-Before Surgery (Fallopian Tube)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage after surgery. Options are the same for before or after surgery \n \n \n\tCode \tDescription \n\t1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s) \n\t1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n\t1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings \n\t1c \tTumour involves 1 or both ovaries or fallopian tubes \n\t1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n\t1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n\t1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n\t2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n\t2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n\t2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n\t3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n\t3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n\t3a1 \tPositive retroperitoneal lymph nodes only \n\t3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n\t3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement \n\t3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n\t3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n\t4 \tDistant metastasis excluding peritoneal metastasis \n\t4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) \n9 \tNot known"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "Clinical extent of disease (Lung only)",
"dataType": "1",
"sensitive": false,
"description": "Options: \nCode \tDescription \n1 \tLocalised \n2 \tRegional spread \n3 \tDistant metastasis \n4 \tNot Known \n \nThis field will be collected for all malignant lung tumours (C34*) registered with a Scottish incidence date from 1.1.2005 to 31.12.2012"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO StageAfter Surgery (Fallopian Tube)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage before surgery. Options are the same for before or after surgery"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO StageAfter Surgery (Cervix only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. \nPreviously this field was known as FIGO Stage, and was collected for all malignant tumours of the cervix (ICD10 C53*) from 1.1.1997 onwards. All tumours recorded with a FIGO stage from 1.1.1997 to 31.12.2004 will exist on the SOCRATES database with a FIGO stage in the After Surgery field. \nFIGO Stage classification change from 1.1.2014 \nSee also FIGO stage before surgery. Options are the same for before or after surgery"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO Stage-\nBefore Surgery (Corpus Uteri only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for Corpus Uteri (C54#) at diagnosis in terms of the pathological and/or clinical findings for Socrates. \nFIGO Stage classification change from 1.1.2014 to include Corpus Uteri \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nCode \tDescription \n1 \tTumour contained to corpus uteri \n1a \tNo or less than half myometrial invasion \n1b \tInvasion equal to or more than half of the myometrium \n2 \tTumour invades the cervical stroma but does not extend beyond the uterus \n3 \tLocal and/or regional spread of tumour \n3a \tTumour invades the serosa of the corpus uteri and/or adnexas \n3b \tVaginal and/or parametrial involvement \n3c \tMetastases to pelvis and/or para-aortic lymph nodes \n3c1 \tPositive pelvic nodes \n3c2 \tPositive para-aortic lymph nodes with or without positive pelvic lymph nodes \n4 \tTumour invades into bladder and/or bowel mucosa and/or distant metastasis \n4a \tTumour invasion bladder and/or bowel \n4b \tDistant metastases including intra-abdominal and/or inguinal lymph nodes \n9 \tNot known"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "Staging Group Testicular",
"dataType": "4",
"sensitive": false,
"description": "This staging group indicates the extent of disease progression of invasive testicular tumours. (ICD10 C62*) with an incident date from 1.1.2015.\n \nOptions are: \nCode \nI \nIA \nIB \nII \nIIA \nIIB \nIIC \nIII \nIIIA \nIIIB \nIIIC \nIS \nNK"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "FIGO Stage – Before Surgery (Ovary only)",
"dataType": "3",
"sensitive": false,
"description": "FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. As with cervix, this is a new field. \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s) \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings \n1c \tTumour involves 1 or both ovaries or fallopian tubes \n \n1C1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n1C2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n1C3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritone \nTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis al fluid \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n3A \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n3A1 \tPositive retroperitoneal lymph nodes only \n3A1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n3A1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n3A2 \tMicroscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement \n3B \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n3C \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n4 \tDistant metastasis excluding peritoneal metastasis \n4A \tPleural effusion with positive cytology \n4B \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) \n9 \tNot Known \n \nFIGO Stage classification change and from 1.1.2014 the options are: \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \n \n\tCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s) \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings \n1c \tTumour involves 1 or both ovaries or fallopian tubes with the following features: \n1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n3a1 \tPositive retroperitoneal lymph nodes only \n3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes including bowel movement \n3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n4 \tDistant metastasis excluding peritoneal metastasis \n4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) \n9 \tNot known"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "STAGE DETAILS",
"columns": [
{
"name": "TNM AJCC (Melanoma)",
"dataType": "4",
"sensitive": false,
"description": "Please refer to staging document \nAJCC – American Joint Committee on Cancer indicates the extent of disease progression of invasive melanoma tumours. \nAJCC is collected for malignant melanomas of the skin (ICD10 C43*) with an incident date from \n1.1.2015 \nOptions for AJCC version 7 are: \nCode \nIA \nIB \nIIA \nIIB \nIIC \nIII \nIIIA \nIIIB \nIIIC \nIV \nX \n \nFrom 01.01.2018 the following options apply for AJCC version 8: \n \n \tCode \n\tIA \n\tIB \n\tIIA \n\tIIB \n\tIIC \n\tIII \n\tIIIA \n\tIIIB \n\tIIIC \n\tIIID \n\tIV \n\tX"
}
],
"description": "STAGE DETAILS (Tumour Level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Independent Primary Tumour",
"dataType": "1",
"sensitive": false,
"description": "Tick box to indicate that a registration has been considered to be an independent primary tumour, regardless of the existence of other registrations with a similar diagnosis."
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Confirmed,Provisional or Deleted",
"dataType": "1",
"sensitive": false,
"description": "Indicates if the record is a provisional registration, a validated / confirmed registration, or a previously deleted registration"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Previous Hospital",
"dataType": "5",
"sensitive": false,
"description": "If transferred to another hospital batch this field will indicate where the provisional registration was last transferred from"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Transformation ICDO3",
"dataType": "5",
"sensitive": false,
"description": "ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behavior. This is recorded for haematological transformations which have occurred since 01.01.2013"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Berg Morphology",
"dataType": "2",
"sensitive": false,
"description": "‘Berg’ grouping for similar morphological families"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Checks",
"dataType": "500",
"sensitive": false,
"description": "Derived from Quality Checks. Indicates date and description of check. Options: \nCode \tDescription \n10 \tNon-specific morphology \n11 \t18QA \n12 \tUnder 25 no treatment \n13 \tNK Staging \n14 \tScheduled QA"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Hospital Code",
"dataType": "5",
"sensitive": false,
"description": "Hospital code is allocated by the system according to the data source where it is presumed the medical records with the most information on the patient will be available. Once this code has been allocated the CRO(s) who work with that institution or area will be able see these provisional records in their batch. This code will usually be associated with the provisional notification before registration, and may not correspond to the registered hospital of diagnosis & Case Ref. no."
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Quality Checks",
"dataType": "2",
"sensitive": false,
"description": "Indicates that a particular quality check has been completed for a particular record. There are a growing number of options due to the development of a more comprehensive quality assurance programme in Cancer Registration."
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Date into Batch",
"dataType": "8",
"sensitive": false,
"description": "The initial date the provisional registration was inserted into the hospital batch for the Cancer Information"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Subcluster Code",
"dataType": "2",
"sensitive": false,
"description": "Officer (CIO) to work with SOCRATES Grouping for similar tumour site families"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Transformation Date",
"dataType": "8",
"sensitive": false,
"description": "Indicates that a haematological transformation has occurred recorded for Scottish incidence year 2013 onwards"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Last Updated Date",
"dataType": "8",
"sensitive": false,
"description": "Date the record was last updated"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Last Updated By",
"dataType": "30",
"sensitive": false,
"description": "Code denoting the last Cancer Information Officer (CIO) who made an amendment to the registration"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Latest Note",
"dataType": "2000",
"sensitive": false,
"description": "Latest comment to be added regarding the tumour. There is a List Notes button available to view previous notes."
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Transfer Date",
"dataType": "8",
"sensitive": false,
"description": "Date provisional registration was last transferred"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "SYSTEM ADMINISTRATION DATA",
"columns": [
{
"name": "Transformation ICD10",
"dataType": "4",
"sensitive": false,
"description": "ICD10 – International Classification of Diseases (10th revision) recorded for haematological transformations which have occurred since 01.01.2013"
}
],
"description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 3",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x8"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Date of Birth (P_DATE_OF_BIRTH)",
"dataType": "8",
"sensitive": false,
"description": "Patient’s full date of birth only. The date of birth at person & tumour level may not be the same. Therefore this field is used for the DOB confirmed to be correct. i.e. the latest used or most commonly used if it is a valid date. The main format inclusive of century is DD-MMM-YYYY e.g. 9th Feb 42 is 09-FEB-1942 this is then saved onto the main oracle table as YYYYMMDD 19420242."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Ethnic Group",
"dataType": "2",
"sensitive": false,
"description": "This field is collected for all registrations with a Scottish incidence date from 1.1.1997 These are used by NHS Scotland organisations for local and national return purposes. \nIt describes the patient’s perception of their Ethnic Group. For patients with more than one registration, the Ethnic Group will be updated to reflect the most recent date option. \nOriginally these were based on the UK Dept. Of Health recommendations (Part of COPPISH SMR patient ID section) \n- From 1.1.1997 to 30.9.2005 Scottish incidence Ethnic Group 1 options: \n \nEthnic Group 1 \nCode \tDescription \n00 \tWhite \n01 \tBlack Caribbean \n02 \tBlack African \n03 \tBlack Other \n04 \tIndian \n05 \tPakistani \n06 \tBangladeshi \n07 \tChinese \n08 \tOther Ethnic Group \n09 \tNot Known \n10 \tRefused \nThe following codes were created to reflect the Scottish Census 2001 categories and were used for a short time in conjunction with the old codes. \n-\tFrom 1.10.2005 to 31.3.2006 Scottish incidence. Ethnic Group 1 options OR Ethnic Group 2 options: \n \nEthnic Group 2 \nCode \tDescription \n1A \tWhite-Scottish \n1B \tWhite-other British \n1C \tWhite-Irish \n1D \tAny other white background \n2A \tAny mixed background \n3A \tIndian \n3B \tPakistani \n3C \tBangladeshi \n3D \tChinese \n3E \tAny other Asian background \n4A \tCaribbean \n4B \tAfrican \n4C \tAny other black background \n5A \tAny other ethnic background \n97 \tRefused/not provided by the patient \n99 \tNot known \n \n-\tFrom 1.4.2006 to 31.3.2010 Scottish incidence Ethnic Group 2 options only \n \n-\tFrom 1.4.2010 to 30.9.2010 Scottish incidence Ethnic Group 2 options OR Ethnic Group 3 options: \nEthnic Group 3 \nCode \tDescription \n1A \tWhite-Scottish \n1E \tWhite-English \n1F \tWhite - Welsh \n1G \tWhite-Northern Irish \n1H \tWhite British \n1J \tWhite-Irish \n1K \tGypsy/Traveler \nIL \tPolish \n1Z \tAny other white ethnic background \n2A \tAny mixed or multiple ethnic groups \n3F \tPakistani, Pakistani Scottish or Pakistani British \n3G \tIndian, Indian Scottish or Indian British \n3H \tBangladeshi, Bangladeshi Scottish or Bangladeshi British \n3J \tChinese, Chinese Scottish or Chinese British \n3Z \tOther Asian \n4D \tAfrican, African Scottish or African British \n4E \tCaribbean, Caribbean Scottish or Caribbean British \n4F \tBlack, Black Scottish or Black British \n4Z \tOther African, Caribbean or Black \n5B \tArab \n5X \tOther Ethnic Group \n98 \tRefused/not provided by the patient \n\t99 \tNot known \n \n \n-\tFrom 1.10.2010 to 30.9.2011 Scottish incidence. Ethnic Group 3 options only \nFurther changes have been made following a review of ethnicity recording in the 2011 Scottish Census. \n \n-\tFrom 1.10.2011 to 31.3.2012 Scottish incidence. Ethnic Group 3 options OR Ethnic Group 4 options \n \nEthnic Group 4 \nCode \tDescription \n1A \tWhite-Scottish \n1B \tWhite- Other British \n1C \tIrish \n1K \tGypsy/Traveller \nIL \tPolish \n1Z \tAny other white ethnic background \n2A \tAny mixed or multiple ethnic groups \n3F \tPakistani, Pakistani Scottish or Pakistani British \n3G \tIndian, Indian Scottish or Indian British \n3H \tBangladeshi, Bangladeshi Scottish or Bangladeshi British \n3J \tChinese, Chinese Scottish or Chinese British \n3Z \tOther Asian, Asian Scottish or Asian British \n4D \tAfrican, African Scottish or African British \n4Y \tOther African \n5C \tCaribbean, Caribbean Scottish or Caribbean British \n5D \tBlack, Black Scottish or Black British \n5B \tArab \n5Y \tOther Caribbean or Black \n6A \tArab, Arab Scottish or Arab British \n6Z \tOther Ethnic Group \n98 \tRefused/not provided by the patient \n99 \tNot known \n- From 1.4.2012 Scottish incidence. Ethnic Group 4 options only"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Person Identifier",
"dataType": "8",
"sensitive": false,
"description": "A unique number which will enable the unequivocal identification of individual cancer patients. It is a sequential number allocated by the computer system SOCRATES (For historical data it will result from person-based linkage). It uniquely identifies each person depending on person-based linkage and is subject to change if linkage is reviewed."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Latest Surname",
"dataType": "20",
"sensitive": false,
"description": "Latest Surname from the last registration completed (if no previous registrations then name used for provisional notification)."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "All Surnames",
"dataType": "30",
"sensitive": false,
"description": "All surnames by which this person has been known. This includes maiden names, aliases or differences in spelling."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Vital Status",
"dataType": "1",
"sensitive": false,
"description": "Living Status of Patient. Options: \nCode \tDescription \n1 \tAlive \n2 \tDead \n3 \tMoved out of Scotland \n6 \tPresumed deceased \n9 \tNot Known"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 4",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x9"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Latest Forename",
"dataType": "30",
"sensitive": false,
"description": "Latest forename from the last registration completed."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Embarkation Date",
"dataType": "8",
"sensitive": false,
"description": "Date of leaving Scotland (or UK) may be entered by the Cancer Information Officer (CIO) or obtained through nationwide NHSCR linkages."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 7",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x12"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Pre-CHI",
"dataType": "1",
"sensitive": false,
"description": "Pre-CHI is a tick box which can be used to break/remove bad UPI linkages."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "OOS (Out of Scotland)",
"dataType": "1",
"sensitive": false,
"description": "This should be ticked to indicate that a patient has died out with Scotland and we have been notified by another Cancer Registry. Death will not be notified through the NRS linkage. This field may explain discrepancy between SOCRATES and ISD warehouse data. This tick box was introduced in the redeveloped SOCRATES."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 6",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x11"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 1",
"dataType": "4",
"sensitive": false,
"description": "Primary Cause of death. Obtained through NRS linkage and are be coded in ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 5",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x10"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Person Comments",
"dataType": "200",
"sensitive": false,
"description": "Not validated but used to record information on the person not provided elsewhere."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Sex (Gender)",
"dataType": "1",
"sensitive": false,
"description": "Sex (Gender) of the patient. The persons state of being Male or Female. For those who have under gone gender re-assignment there may be a mismatch recorded between sex and ICD10 code. Options:\nCode Description\n0 Not Known (i.e. indeterminate sex, includes intersex)\n1 Male\n2 Female\n9 Not Specified (includes not states by patient, or not recorded)"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Derived UPI (P_DERIVED_UPI)",
"dataType": "10",
"sensitive": false,
"description": "A Unique Patient Identifier (UPI) was determined to be the CHI number which was most current at the time the indexes were linked ie. The record with the latest date of acceptance on a GP record. 10 digit number consists of 6-digit DOB (DDMMYY) followed by 4 check digits (9th digit denotes sex. 1,3,5,7 or 9 =male, 2,4,6,8 or 0 =female). This field is automatically populated by ascertaining the derived UPI by linking the CHI number held within the Registration Diagnosis screen directly to the CHI database. The Socrates system is also automatically CHI seeded during production run linkage."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Date of Death",
"dataType": "8",
"sensitive": false,
"description": "Date of patient’s death may be entered by the Cancer Information Officer (CIO) or obtained through linkage to the National Records of Scotland (NRS). The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS. Format DD-MMM-YYYY."
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "PERSON RECORD",
"columns": [
{
"name": "Cause of Death 2",
"dataType": "4",
"sensitive": false,
"description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x7"
}
],
"description": "PERSON RECORD (Person Level)"
},
{
"name": "Source Data",
"columns": [
{
"name": "Forenames",
"dataType": "30",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Create Point",
"dataType": "6",
"sensitive": false,
"description": "Indicates the creation rule decision (NEW – new tumour, MP1 – different at sub cluster code etc)"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Surname",
"dataType": "20",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Sex",
"dataType": "1",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Incidence Date",
"dataType": "8",
"sensitive": false,
"description": "As defined previously."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 8",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "SOC link",
"dataType": "6",
"sensitive": false,
"description": "Socrates link weight"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Date Of Birth",
"dataType": "10",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Accession Number",
"dataType": "8",
"sensitive": false,
"description": "Unique number generated for CDP (Cancer Data Processing) for all notifications."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Site – short desc",
"dataType": "130",
"sensitive": false,
"description": "Additional information from the Pathology text i.e. site of tumour/excision/substance"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Type",
"dataType": "2",
"sensitive": false,
"description": "Record Type of data. Options: \n \nCode \tDescription \n00 \tSMR00 \n10 \tSMR01 \n11 \tPrivate Hospital \n2% \tPathology \n3% \tRadiotherapy \n51 \tOncology \n52 \tCommunity Prescribing \n62 \tCervix Screening \n70 \tChemocare \n75 \tCancer Waiting Times \n90 \tNRS death notification - quarterly \n98 \tNRS death notification - annual"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Local Patient ID",
"dataType": "12",
"sensitive": false,
"description": "Local ref. no such as lab no"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Hospital Converted",
"dataType": "5",
"sensitive": false,
"description": "Hospital code converted from text input if pathology data or 3 digit code if WGH radiotherapy data"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures - OP2",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "GP Code",
"dataType": "5",
"sensitive": false,
"description": "GP Practice code"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Address",
"dataType": "200",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP3",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP7",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Stage",
"dataType": "2",
"sensitive": false,
"description": "Staging information if available"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP4",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 7",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Morphology",
"dataType": "7",
"sensitive": false,
"description": "Type code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Date of Admission",
"dataType": "8",
"sensitive": false,
"description": "(SMR01) Hospital admission date"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 2",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Sub Code",
"dataType": "2",
"sensitive": false,
"description": "Subcluster Code grouping of cancer site codes - used for the elimination of similar notifications."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 4",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Sent By",
"dataType": "40",
"sensitive": false,
"description": "Consultant code, Clinician certifying death on GRO records, Hospital areas on Pathology reports etc"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "ICD-10 Conv. Site",
"dataType": "6",
"sensitive": false,
"description": "Converted to ICD-10 code from SNOMED and ICD-9 codes"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 3",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Converted Morphology",
"dataType": "5",
"sensitive": false,
"description": "Converted from SNOP codes (WGH radiotherapy) or eg M-80003 to 80003"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "CHI",
"dataType": "10",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP5",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Hospital Unconverted",
"dataType": "5",
"sensitive": false,
"description": "Original code or text received from source data."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Previous Name",
"dataType": "20",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 5",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures - OP1",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Ethnic Group",
"dataType": "2",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Load num",
"dataType": "8",
"sensitive": false,
"description": "Production run load number. Indicates when source data record was processed"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "New Data",
"dataType": "1",
"sensitive": false,
"description": "Describes the outcome of the addition of a source data record. Options: \n \nCode \tDescription \nD \tNon-cancer death for unknown person \nE \tError has been caused by this record \nJ \tDuplicate data \nM \tData rejected by multiple primary rules \nP \tData used to create provisional record \nS \tData rejected by secondary rules \nX \tSupplementary data added to an open provisional record"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Pathology",
"dataType": "10000",
"sensitive": false,
"description": "Full pathology text."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP6",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Size",
"dataType": "2",
"sensitive": false,
"description": "Tumour size if available"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Specialty or Req Type",
"dataType": "2",
"sensitive": false,
"description": "Specialty for SMR01 data & Request Type for pathology data e.g. A for autopsy"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Postcode",
"dataType": "8",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Data Source",
"dataType": "7",
"sensitive": false,
"description": "Main source of notification e.g. GRO-S, SMR01 or source location code of hospital of pathology/radiotherapy"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 6",
"dataType": "6",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Site – long desc",
"dataType": "130",
"sensitive": false,
"description": "Additional information from the Pathology text i.e. type of excision From Community Prescribing data this displays the prescribed drug."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "TNM",
"dataType": "18",
"sensitive": false,
"description": "TNM information if available"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Int link",
"dataType": "6",
"sensitive": false,
"description": "Not used"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Unconverted Site 1",
"dataType": "7",
"sensitive": false,
"description": "Site code used for notifications before any conversions."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Marital Status",
"dataType": "1",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Berg Group",
"dataType": "2",
"sensitive": false,
"description": "Berg morphology type grouping code used to eliminate multiple primary/duplicate notifications"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Morphology desc",
"dataType": "130",
"sensitive": false,
"description": "Morphology description"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Source DOD",
"dataType": "8",
"sensitive": false,
"description": "Date of death if available at source"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Ward",
"dataType": "20",
"sensitive": false,
"description": "Ward number if available"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "NHS Number",
"dataType": "16",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Procedures – OP8",
"dataType": "4",
"sensitive": false,
"description": "Operation or procedure code used for notifications from SMR01."
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Case Ref No",
"dataType": "10",
"sensitive": false,
"description": "(Hospital Patient ID) As defined previously"
}
],
"description": "Source Data"
},
{
"name": "Source Data",
"columns": [
{
"name": "Derived CHI",
"dataType": "11",
"sensitive": false,
"description": "As defined previously"
}
],
"description": "Source Data"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Death Certificate Initiated",
"dataType": "1",
"sensitive": false,
"description": "Death certificate initiated indicates that the case has FIRST come to light ONLY as a result of a death, as assessed from the source records available at the time of confirming the registration. However, subsequent evidence may be discovered ‘out in the field’. Options:\n\nCode \tDescription \n0 \tNo \n1 \tYes"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Tumour Type - ICDO Code",
"dataType": "6",
"sensitive": false,
"description": "ICDO - International Classification of Diseases for Oncology. Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICD-O morphology code and a fifth digit which denotes behaviour of the tumour. \nAll registrations with a Scottish incidence date up to and including 31.12.1996 should be classified according to the ICDO classification. \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "CIO of Registration",
"dataType": "30",
"sensitive": false,
"description": "The code identifies the Cancer Information Officer (CIO) who first confirms the registration. This field remains unchanged regardless of any subsequent amendments by other staff. This is automatically allocated by the Socrates system."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Microinvasive",
"dataType": "1",
"sensitive": false,
"description": "Microinvasive is used to describe a degree of invasion which is not associated with any risk of nodal metastasis and is sufficiently small to treat by local or conservative means. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2005"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Tumour Type - ICDO(3) Code",
"dataType": "6",
"sensitive": false,
"description": "ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behaviour. \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site \nPlease note there are some differences between ICDO(2) and ICDO(3) including the change in behaviour of certain tumour types from one classification to the other. This field will be completed for all registrations with a Scottish incidence date from 1.1.2006. Registrations with a Scottish incidence date from 1.1.2012 onwards, will adopt the 2011 updated version of codes for ICDO3."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Gleason Tertiary",
"dataType": "1",
"sensitive": false,
"description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011. Options: \nCode \tDescription \n1 \tTertiary 1 \n2 \tTertiary 2 \n3 \tTertiary 3 \n4 \tTertiary 4 \n5 \tTertiary 5 \n9 \tNot Known \n \nThe tertiary component of the Gleason score was previously not recorded but indicates a generally more aggressive pattern of the tumour and in some cases may be preferred as a measure with the Gleason Major to derive a Gleason score. \nTo be completed for all prostate cases with an ICD10 code of C61."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Most Valid Basis of Diagnosis",
"dataType": "1",
"sensitive": false,
"description": "Most Valid Basis of diagnosis indicates the method judged to have best provided or validated the diagnosis during the course of the illness. Options: \nCode \tDescription \n1 \tClinical only \n2 \tClinical investigation (including x-ray, ultrasound, etc.) \n3 \tExploratory surgery/endoscopy/autopsy (without concurrent or previous histology) \n4 \tSpecific biochemical and/or immunological tests (e.g. Prostate Specific Antigen (PSA) - for prostate cancer or Bence Jones Protein (BJP) - for Myeloma) \n5 \tCytology (including blood film or bone marrow aspirate) \n6 \tHistology of metastasis \n7 \tHistology of primary \n8 \tAutopsy (with concurrent or previous histology) \n9 \tNot Known \n10 \tDeath certificate only \n \nThe methods of diagnosis are listed in essentially ascending order of validity, microscopic methods having greater validity than non-microscopic methods. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Gleason Minor",
"dataType": "1",
"sensitive": false,
"description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011 onwards. Options: \n \nCode \tDescription \n1 \tMinor 1 \n2 \tMinor 2 \n3 \tMinor 3 \n4 \tMinor 4 \n5 \tMinor 5 \n9 \tNot Known \n \nPreviously, this was recorded as a combined Gleason score with the Gleason Major component. (See above). These are now recorded separately. \nTo be completed for all prostate cases with an ICD10 code of C61."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Histological \nVerification",
"dataType": "1",
"sensitive": false,
"description": "Histological Verification is microscopic confirmation of the histological or cytological diagnosis (including examination of peripheral blood film). For post-97 registrations, HV-verified should correspond with Most Valid Basis Of Diagnosis options 5-8. \nNOTE - CIN 3 should only be registered if the diagnosis is based on histology, not cytology alone. Options: \n \nCode \tDescription \n1 \tVerified \n2 \tNot verified"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "ENCR Incident Date",
"dataType": "8",
"sensitive": false,
"description": "ENCR (European Network of Cancer Registries) incidence date will be recorded from 01.01.2019. \n \nENCR Incidence Date definition; \n \n“The date of the first event (7 to choose from outlined below) to occur chronologically should be chosen as ENCR incidence date. If an event of higher priority occurs within 3 months of the date initially chosen, the date of the higher priority event should take precedence.” \n \nThe date of the first event of the 7 listed to occur chronologically should be chosen as ENCR incidence date. If an event of higher priority occurs within three months of the date initially chosen, the date of the higher priority event should take precedence."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Tumour Site – ICDO(2) / ICDO(3) Code",
"dataType": "6",
"sensitive": false,
"description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Similar to ICD10 site code, but there are differences in the site code ranges. ICDO(2) does not include type specific codes such as lymphomas (C82-C85) or Kaposi’s sarcoma (C46), but has the ability to code such neoplasms more precisely to their site of origin. All registrations should now be completed with an ICDO(2) site code, regardless of incidence. This field is collected for all registrations with a Scottish incidence date from 1.1.1997. With the introduction of ICDO(3), it should be noted that there is no change in the codes for SITE from ICDO(2) to ICDO(3)."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Side (Laterality)",
"dataType": "1",
"sensitive": false,
"description": "This indicates the side or laterality of origin (i.e. left or right) in the case of paired organs. (e.g. breast, kidney, limb, lung, ovary, testis). Acceptable SIDE is based on the current UKACR table of Laterality. Tumours existing in both sides of a paired organ should be registered twice for Left and Right. The only paired organs to be treated as a single site (bilateral) are tumours of the ovary and Wilms tumour of the kidney or nephroblastoma. (ICDO(3) 8960/3) Options: \nCode \tDescription \n0 \tNot applicable (non paired organs) \n1 \tRight \n2 \tLeft \n3 \tBilateral \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Method of First Detection",
"dataType": "1",
"sensitive": false,
"description": "Method of first detection indicates how the tumour was first detected. \n \nOptions: \nCode \tDescription \n1 \tScreening examination \n2 \tIncidental finding (on examination or at surgery for an unrelated reason) \n3 \tClinical presentation (with relevant symptoms) \n4 \tIncidental finding at autopsy (previously unsuspected) \n5 \tInterval cancer \n8 \tOther \n9 \tNot Known \n \nInterval cancer is an option introduced in the redeveloped SOCRATES in 2006. It describes when a primary tumour with histological confirmation is diagnosed in the interval following a negative screening episode and before the next scheduled screening examination. The \"interval\" relates to the interval between screenings rather than the interval between separate tumour occurrences. \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Gleason Major",
"dataType": "1",
"sensitive": false,
"description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011 onwards. Options: \n \nCode \tDescription \n1 \tMajor 1 \n2 \tMajor 2 \n3 \tMajor 3 \n4 \tMajor 4 \n5 \tMajor 5 \n9 \tNot Known \n \nPreviously, this was recorded as a combined Gleason score with the Gleason Minor component. (See above). These are now recorded separately. \nTo be completed for all prostate cases with an ICD10 code of C61."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Date of Registration",
"dataType": "8",
"sensitive": false,
"description": "The date the Cancer Information Officer confirms a registration on the SOCRATES cancer registration database, having passed all validation checks. This is automatically allocated by the Socrates system."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Grade or Cell type",
"dataType": "2",
"sensitive": false,
"description": "Grade or cell type indicates the degree of differentiation of malignant tumours or the T-cell & B-cell designation for lymphomas and leukaemias and is sometimes recorded as the sixth digit of the ICDO morphology code, although this is not recorded on SOCRATES. \n \nBreast options: \nCode \tDescription \n1 \tGrade 1 / low grade \n2 \tGrade 2 / intermediate grade \n3 \tGrade 3 / high grade \n9 \tNot Known \n \nProstate -‘Gleason Score’ Options: 2 -10 or 0 (Not known). \nUp to Scottish incidence date 31.12. 2010, the Gleason score will be recorded as the sum of the \nGleason Major score and Gleason Minor score. From 1.1.2011 Scottish incidence date onwards, the Grade or Cell type field will contain the Gleason Major, Minor and Tertiary score separately. Options: 1 - 5 or 9 (Not known). \nTo be completed for all prostate cases with an ICD10 code of C61. \n\nKidney – ‘Fuhrman’/ISUP (VANCOUVER) Options: \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \nWHO (Brain and CNS) Options: \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \n \n \n \nGIST (sarcoma GIST tumours only) Options: \nCode \tDescription \nGX \tGrade cannot be assessed \nG1 \tLow grade; mitotic rate 5/50 per high-power field (HPF) or less \nG2 \tHigh grade; mitotic rate > 5/50 HPF \n \nICD-O/UICC Options: \n\tCode \tDescription \n\t1 \t(Well) differentiated \n\t2 \tModerately (well) differentiated \n\t3 \tPoorly differentiated \n\t4 \tUndifferentiated, anaplastic \n\t5 \tT-Cell (inc. T-precursor) \n\t6 \tB-Cell (inc. Pre-B, B-precursor) \n\t7 \tNull Cell ( Non T-non B, leukaemias only) \n\t8 \tNatural killer (NK) Cell \n\t9 \tGrade/Cell type or differentiation not determined, not stated or not applicable. \n\nTo be used for all diagnostic sites other than those above. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Scottish Incidence Date",
"dataType": "8",
"sensitive": false,
"description": "Scottish Incidence date is the date that the cancer in question becomes formally known to NHS \nScotland. Previously known as ‘date treatment commenced’ and/or ‘Incidence Date’. Can be termed \n“date of diagnosis” \n(A) For patients seen as outpatients and/or day cases and/or inpatients (other than long stay or residential), it is the earliest available date from the following: - Date of first consultation as an outpatient. - Date of first pathology report confirming diagnosis - Date of admission to hospital. \n- Date of hospital-initiated treatment \nIf none of the above dates apply or can be established, the date of diagnosis (or best estimate) should be used. \n(B)\tFor long stay or residential patients, or patients receiving care at home, it is the date of diagnosis (or best estimate). \n(C)\tFor death certificate only cases (when follow-up attempts have been unsuccessful), and for cases first diagnosed at autopsy (unsuspected during life), it is the date of death."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "ENCR Event",
"dataType": "1",
"sensitive": false,
"description": "ENCR Event type has to be chosen from table below: \n \n\tCode \tDescription \n\t1 \tDate of 1st histological/cytological confirmation \n\t2 \tDate of admission to hospital \n\t3 \tDate of 1st consultation at outpatient clinic \n\t4 \tDate of diagnosis other than 1, 2, 3 (incl. diagnostic imaging that confirms registerable disease) \n\t5 \tTreatment date \n6 \tDate of Death \n7 \tDate of death - autopsy"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Grade Classification Used",
"dataType": "1",
"sensitive": false,
"description": "Indicates the classification system used for grading tumour. Options: \n \nCode \tDescription \n1 \tGrading for breast cancer (ICD10 C50 and D05). \n2 \tICD-O/UICC \n3 \tGleason Score (Prostate only – ICD10 C61) \n4 \tBloom and Richardson (Breast only) *NOW OBSOLETE* \n5 \tFuhrman nuclear grade/ISUP (VANCOUVER) (Renal cell carcinomas of kidney – ICD10 C64 \n6 \tWHO grade (Brain and CNS only - ICD10 C70-C72, D32 – D33, D35.2 – D35.4, D42 – D43, D44.3 – D44.5 \n7 \tGIST only C15*, C16*, C17*, C18*, C20*, C25*, C269, C48.1, C762, C80* and morphology 89363 \n8 \tOther \n9 \tNot determined/not stated/not applicable \n \nFor code 1 note: \nThe Nottingham grading system (previously option 1) and the Bloom and Richardson grading system (previously option 4) have been combined, as one is essentially a modification of the other. The new Grading for breast cancer (option 1) will be used from the introduction in October 2010 of the newly developed Socrates version and should be completed for all cases of breast cancer. Option 4 is now obsolete. All previously registered cases of Bloom and Richardson Grade have been electronically amended to record the new option 1. \n \nFor code 5 note: \nFuhrman nuclear grade was introduced as an option in Socrates in 2006. Previously, this classification was recorded under [8] Other. ISUP (VANCOUVER) was introduced as an option in Socrates in 2014. \n \nFor code 6 note: \nThis was previously recorded under [8] Other with a note of grade in the Admin screen. To be collected for records from 1.1.2006 Scottish incidence onwards. \nFor code 7 note: \nThis was introduced for 2016 registrations. \n For most other cancers, the ICD-O/UICC grading system is used. If the grade of differentiation is explicitly enumerated in the pathology report it should be recorded as such. If it is not explicitly stated, it may be derived from the text of the pathology report according to the definition options stated for Grade below. Grade is recorded every time this information is available except when T or B cell origin is provided for lymphomas & leukaemias. In this event, the T or B - cell origin has priority and also has options stated in Grade definition below. \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Tumour Type - ICDO(2) Code",
"dataType": "6",
"sensitive": false,
"description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(2) morphology code and a fifth digit which denotes behaviour. All registrations with a Scottish incidence date from 1.1.1997 to 31.12.2005 should now be completed with an ICD(O)2 morphology code. There are some differences between ICDO and ICDO(2) including the change in behaviour of certain tumour types from one classification to the other."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Diagnostic code - ICD9 Code",
"dataType": "6",
"sensitive": false,
"description": "ICD9 – International Classification of Diseases (9th revision). All registrations with a Scottish incidence date up to and including 31.12.1996 should be classified according to the ICD9 classification. This field should also be completed for all “Death Certificate Only” (DCO) cases with a Scottish incidence date up to and including 31.12.1999."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Death Certificate Only",
"dataType": "1",
"sensitive": false,
"description": "This indicates that the case has been registered from the death certificate only, since no other evidence of the tumour can be found. i.e. No information from medical records, and no source records other than the death record. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes"
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "DIAGNOSIS DETAILS",
"columns": [
{
"name": "Diagnostic code - ICD10",
"dataType": "6",
"sensitive": false,
"description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Similar to ICD10 site code, but there are differences in the site code ranges. ICDO(2) does not include type specific codes such as lymphomas (C82-C85) or Kaposi’s sarcoma (C46), but has the ability to code such neoplasms more precisely to their site of origin. All registrations should now be completed with an ICDO(2) site code, regardless of incidence. This field is collected for all registrations with a Scottish incidence date from 1.1.1997. ICD10 – International Classification of Diseases (10th revision). All registrations with a Scottish incidence date from 1.1.1997 onwards should be completed with an ICD10 (version 3) site code. Registrations with a Scottish incidence date from 1.1.2014 will be taking into account the modified version of ICD10 (version 4) and using these codes in line with other NHS Scotland organisations for local and national return purposes."
}
],
"description": "DIAGNOSIS DETAILS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Date of Death",
"dataType": "8",
"sensitive": false,
"description": "See Person screen definitions."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Person Identifier",
"dataType": "8",
"sensitive": false,
"description": "A unique number which will enable the unequivocal identification of individual cancer patients. It is a sequential number allocated by the computer system SOCRATES (For historical data it will result from person-based linkage)."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "NHS Number",
"dataType": "16",
"sensitive": false,
"description": "National Health Service (NHS) number is the identifier allocated to an individual to enable unique identification within the UK for NHS health care purposes. (Part of COPPISH SMR patient ID section)."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Case Reference (Hospital Record ID)",
"dataType": "10",
"sensitive": false,
"description": "Hospital Patient Health Record Identifier was previously Case Reference Number and refers to the Case Ref. No. from the institution of diagnosis. Part of COPPISH SMR patient ID section & is combined with Health Records System Identifier to make up the ‘Patient Record Identifier’ which is used to uniquely identify a patient within a health register or health records system such as PAS."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "GP Practice Code",
"dataType": "5",
"sensitive": false,
"description": "Practice code of patient’s GP (Part of COPPISH SMR patient ID section). Each GP practice in Scotland is identified by a unique code. The practice code is a four digit code plus a check digit with ranges of code allocated to each Health Board. This field is collected for all registrations with a Scottish incidence date from 1.1.1997"
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Address at Diagnosis",
"dataType": "10",
"sensitive": false,
"description": "Usual full address of residence of the person on the Scottish incidence date i.e. the residence at which the person resides for the majority of time. Must be within Scottish boundaries. This field is collected for all registrations with a Scottish incidence date from 1.1.1997."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Forenames at Diagnosis",
"dataType": "30",
"sensitive": false,
"description": "Forenames or initials of the patient on the Scottish incidence date. May include a hyphen or an apostrophe, e.g. Mary-Jane or T’Pau. Each forename/initial to be separated by a space."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Ethnic Group",
"dataType": "2",
"sensitive": false,
"description": "See Person screen definitions."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Postcode at Diagnosis",
"dataType": "8",
"sensitive": false,
"description": "Postcode for the usual place of residence of the person on the Scottish incidence date. Must be Scottish postcode according to ISD postcode reference files."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Marital Status",
"dataType": "2",
"sensitive": false,
"description": "Marital Status has been recorded since registration began, the options originally part of the COPPISH SMR patient ID section. Options:\nOption 1 \nDescription \nNever married (single) \nMarried (includes separated) \nWidowed \nOther (includes divorced) \nNot Known \n \nTo take account of the Scottish Government Core Survey Question relating to “Legal Marital Status”, this field has been reviewed. \nFrom 1.4.2012 to 31.3.2013 Scottish incidence date, registrations may be recorded with Option 1 or Option 2: \n \nOption 2 \nDescription \nNever married nor registered civil partnership \nMarried \nRegistered civil partnership \nSeparated, but still married \nSeparated, but still in civil partnership \nDivorced \nDissolved civil partnership \nWidowed \nSurviving civil partner \nOther \nNot Known \n \nFrom 1.4.2013 Scottish incidence, all registrations must use the new coding option."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Date of Birth",
"dataType": "8",
"sensitive": false,
"description": "See Person screen definitions."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "CHI Number",
"dataType": "10",
"sensitive": false,
"description": "The Community Health Index (CHI) is a population register which is used for health care purposes. The CHI number uniquely identifies a person on the index. Prior to January 1997, there were 8 indexes, each"
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "All Surnames",
"dataType": "30",
"sensitive": false,
"description": "All surnames by which this person has been known. This includes maiden names, aliases or differences in spelling. The Cancer Information Officer (CIO) cannot amend this field."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Sex (Gender)",
"dataType": "1",
"sensitive": false,
"description": "See Person screen definitions."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Record Number",
"dataType": "8",
"sensitive": false,
"description": "Computer generated number given to all new provisional registrations & pre-97 registrations. The confirmed registration will retain this number which uniquely and permanently identifies each tumour registration. Note this is different from the person ID number."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "IDENTIFICATION AT DIAGNOSIS",
"columns": [
{
"name": "Surname at Diagnosis",
"dataType": "20",
"sensitive": false,
"description": "Surname of the patient on the Scottish incidence date. May include a hyphen or an apostrophe e.g. Wilmot-Brown or O’Brien."
}
],
"description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Nodes \nExamined \n(Breast)",
"dataType": "1",
"sensitive": false,
"description": "Pathological nodal status -Indicates if the regional lymph nodes were examined. Associated with invasive breast cancer only. Options: \nCode \tDescription \n0 \tNo \n1 \tYes, a sample \n2 \tYes, axillary node clearance \n9 \tNot Known \n \nThis field is collected for all malignant tumours of the breast (ICD10 C50*) with a Scottish incidence \ndate from 1.1.1997 to 31.12.2012"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Number Positive/Total number involved/Positive (head and neck, colorectal, lung, melanoma or breast)",
"dataType": "2",
"sensitive": false,
"description": "Pathological nodal status -Indicates how many of the regional lymph nodes were positive/involved - Options: 0-99 or NK - not known\nRecoded for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Number examined/Total number examined (head and neck, colorectal, lung, melanoma or breast)",
"dataType": "2",
"sensitive": false,
"description": "Pathological nodal status - Indicates how many regional lymph nodes were examined. Options: 0-99 or NK - not known \nRecoded for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Breslow thickness size (mm)",
"dataType": "4",
"sensitive": false,
"description": "Breslow thickness (in mm, to 2 decimal places or 99.99 (Not known) will be recorded for all cutaneous melanomas (C43*) with a Scottish incidence date from 1.1.2005."
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Performance Status",
"dataType": "1",
"sensitive": false,
"description": "Performance status is an overall assessment of the functional/physical performance of the patient. This is a five point scale in which ‘0’ denotes normal activity and ‘4’ a patient who is 100% bed ridden. This item may occur more than once throughout a patient’s record however, the performance status to be recorded is that closest to Scottish incidence date but prior to treatment. If the performance status falls between two scores then the worst performance status should be taken. This field cannot be derived. This field applies to all registerable invasive cancers C000 – C97X (excluding non melanoma skin C44) and brain cancers D180, D32*, D33*, D352, D353, D354 with a Scottish incidence date from 1.1.2017. \n \n \nOptions: \n\tCode \tValue \n\t0 \tFully active, able to carry on all pre-disease performance without restriction \n\t1 \tRestricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work \n\t2 \tAmbulatory and capable of self care but unable to carry out any work activities: up and about more than 50% of waking hours \n\t3 \tCapable of only limited self care, confined to bed or chair more than 50% of waking hours \n\t4 \tCompletely disabled, cannot carry on any self care, totally confined to bed or chair \n\t9 \tNot recorded"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Oestrogen \nReceptor Status (Breast only)",
"dataType": "1",
"sensitive": false,
"description": "Oestrogen Receptor Status (or ER status) should be available for breast cases (ICD10 C50 or D05) diagnosed histologically. i.e. confirmed from biopsy, surgical excision or histology of nodes or metastases. Receptor status tests are usually performed on the biopsy specimen and generally issued as a supplementary report after the initial reporting of the biopsy. \n \nRecord status regardless of any qualifying statements e.g. weakly positive. \n \nOptions: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n \nThere are several different scoring systems but the recommended and usual method for both ER and PR testing is the Quick (Allred) score. \nAllred score: The scores are summed to give a maximum of 8. Generally reports will state results of ER/PR status as positive or negative for example - “ER status: positive 5/8” but some may only provide scores which can be referenced to known positive and negative ranges. \nA score of 0-1 indicates negative result \nA score of 2–3 positive (weak) \nA score of 4–6 positive (moderate) \nA score of 7–8 positive (strong) \n \nER status may also be recorded as a value from which the status can be derived as shown below: \n \nMethod (assay) ER positive ER negative \nDCC > or = 20 fmols ER/mg protein < 20 fmols ER/mg protein EIA > or = 20 fmols ER/mg protein < 20 fmols ER/mg protein \nERICA > or = 10% positive staining < 10% positive staining \n \nThis field is collected for all registrations of malignant breast tumours (C50) with a Scottish incidence date from 1.1.1997 and additionally for all in situ breast tumours with a Scottish incidence date from 1.1.2009. \n \nNote: This field was moved from the Diagnosis screen in Socrates to the Stage screen in October 2010."
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Progesterone \nReceptor Status (Breast only)",
"dataType": "1",
"sensitive": false,
"description": "Progesterone Receptor Status (PR or PgR status) should be available for all breast cases (ICD10 C50 or D05) diagnosed histologically. i.e. confirmed from biopsy, surgical excision or histology of nodes or metastases. Receptor status tests are usually performed on the biopsy specimen and generally issued as a supplementary report after the initial reporting of the biopsy. See method of testing as in Oestrogen Receptor Status. Options: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n \nIf positive (PgR+ or PR+), the cancer should respond well to hormone suppression treatments. If the score is negative (PgR- or PR-), then the tumour will not be driven by progesterone, and HER2 status may well be sought to determine the most effective treatment. \n \nThis field is collected for all registrations of malignant or in situ breast tumours (C50 or D05) with a Scottish incidence date from 1.1.2009."
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Positive \nNodes/Nodes involved (head and neck, colorectal, lung, \nmelanoma or breast)",
"dataType": "1",
"sensitive": false,
"description": "Pathological nodal status -Indicates if any of the regional lymph nodes were positive/involved Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \n \nThis field is collected for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Regional Lymph nodes assessment",
"dataType": "1",
"sensitive": false,
"description": "Pathological nodal status -Indicates what regional lymph nodes were examined. Associated with invasive head and neck, colorectal, lung, melanoma or breast cancer. Options: \nCode \tDescription \n0 \tNo regional lymph nodes removed or aspirated \n1 \tAspiration or biopsy of regional lymph node \n2 \tSentinel lymph node biopsy \n3 \tRegional lymph node dissection \n9 \tNot Known \n \nThis field is collected for all malignant tumours (ICD10 C00# - C14# or C18# - C21# or C30# - C34# or C43# or C50# or C760 with a Scottish incidence date from 1.1.2013"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "HER2 status \n(Breast only)",
"dataType": "1",
"sensitive": false,
"description": "There are two tests available to measure over-expression of HER2 receptors in a tumour cell. \n \na)\tImmunochemistry HER2 receptor test (IHC) shows how much of the HER2 protein is present in a tumour cell. \nb)\tFluorescence in-situ hybridisation (FISH).If the HER2 test results are borderline this additional more accurate test, will be carried out to confirm a positive or negative result. \n \nOptions: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n This field is collected for all registrations of malignant or in situ breast tumours (C50* or D05*) with a Scottish incidence date from 1.1.2009"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "PSA Level",
"dataType": "8",
"sensitive": false,
"description": "The PSA test is a blood test that can help diagnose prostate problems, including prostate cancer. It measures the amount of prostate specific antigen in blood. It is normal to have a small amount of PSA in the blood but a raised PSA level may suggest a prostate problem. \n \nThis field applies to prostate cancer only (C61X) with a Scottish incidence date from 1.1.2017. The PSA recorded should be that measured on the date of diagnosis and prior to treatment. If there is no PSA at the time of diagnosis and treatment has commenced take the PSA level prior to referral, this may be taken by the GP. \n \nThis is a numeric value between 0.1 – 9999999.9 and not known set to 0. This field cannot be derived."
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Serum Marker",
"dataType": "2",
"sensitive": false,
"description": "This denotes the nadir levels as obtained after orchiectomy. This applies to testicular cancers only (C62#) with a Scottish incidence date from 1.1.2017. This field cannot be derived. \n \nOptions: \nS0 \tSerum marker study levels within reference range \nS1 \tLDH <1.5 * N and hCG <5,000(mIU/ml) and AFP < 1000 (ng/ml) \nS2 \tLDH 1.5-10* N or hCG 5,000 – 50,000 (mIU/ml) or AFP 1,000 -10,000 (ng/ml) \nS3 \tLDH >10 * N or hCG >50,000(mIU/ml) or AFP >10,000 (ng/ml) \nX \tNot known \n \nThis can be used in conjunction with TNM staging to derive Testicular Stage."
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Pathological Tumour Size (mm)",
"dataType": "3",
"sensitive": false,
"description": "Pathological tumour size is the maximum diameter in mm of the invasive component of the tumour in the fresh or fixed state on the histological preparation. If the two measurements are discrepant then that obtained from the histological (fixed) section(s) should be recorded. The tumour (not the excised specimen) with the greatest diameter should be used. Option range: 000-999 or NK - not known. This field is collected for all malignant tumours of the breast (ICD10 C50*) with a Scottish incidence date from 1.1.1997 and all malignant tumours of testis (ICD10 C62*) from 1.1.2015"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Clinical Tumour Size (mm)",
"dataType": "3",
"sensitive": false,
"description": "Clinical tumour size is the maximum diameter in mm of the invasive component of the tumour, or where multiple tumours exist, the maximum diameter in mm of the largest tumour. Option range: 000-999 or NK - not known\nThis field is collected for all malignant hepatocellular tumours of the liver (ICD10 C220) with a Scottish incidence date from 1.1.2014"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "OTHER CONTRIBUTING FACTORS",
"columns": [
{
"name": "Clarks level",
"dataType": "2",
"sensitive": false,
"description": "Clarks level is a measure of the depth of invasion into the skin and will be recorded for all cutaneous melanomas (C43*) with a Scottish incidence date from 1.1.2005. Clarks level options: \n \nCode \tDescription \nI \tClarks I \nII \tClarks II \nIII \tClarks III \nIV \tClarks IV \nV \tClarks V \n9 \tNot Known"
}
],
"description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old GRO(S) Flag",
"dataType": "1",
"sensitive": false,
"description": "Indicates if a GRO(S) match has been made to update record"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Occupation",
"dataType": "3",
"sensitive": false,
"description": "Occupation of patient at time of registration. This is a 3 digit code according to OPCS classifications. Range: 001-350, 666 &777. Only collected on pre-SOCRATES data."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Output Area 2001",
"dataType": "4",
"sensitive": false,
"description": "STATISTICAL DATA (used for all registrations)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Social Class",
"dataType": "1",
"sensitive": false,
"description": "Social Class - Derived from the occupation code of the patient on the Scottish incidence date"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "HB Residence number",
"dataType": "1",
"sensitive": false,
"description": "As above"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Grid Ref Northing",
"dataType": "6",
"sensitive": false,
"description": "Local government district (1 – 68)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Urban / Rural",
"dataType": "2",
"sensitive": false,
"description": "ED Grid Reference - Derived from the Enumeration District of the patient on the Scottish incidence date. The northing with the origin based in the Scilly isles."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old Can Reg No.",
"dataType": "6",
"sensitive": false,
"description": "Sequential number allocated by each regional registry computer system (not unique)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Output Area 1991",
"dataType": "10",
"sensitive": false,
"description": "NOTE: postcode-derived variables are of uncertain reliability and are due to be further developed."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old Batch Number",
"dataType": "4",
"sensitive": false,
"description": "Batch numbers allocated to data prior to DTC 1997"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Local Govt District",
"dataType": "2",
"sensitive": false,
"description": "A letter (cypher) relating to the locale, of the resident population, represented as one of 15 Scottish Health Board Areas"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old Hospital code",
"dataType": "5",
"sensitive": false,
"description": "Institution code of institution of registration - Mandatory for Pre-97 tumours."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "HB Residence cypher",
"dataType": "7",
"sensitive": false,
"description": "Output areas are the smallest geographical unit for which Census data are available There were 42,604 output areas at the 2001 Census with a mean population size of 119 people. The smallest output area represented 50 people and the largest 2,357 people. This wide variation was due to a few large output areas with populations in communal establishments. However, the population sizes have become increasingly variable in the years since the 2001 Census due to population migration."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Local Council Area",
"dataType": "7",
"sensitive": false,
"description": "ED Grid Reference - Derived from the Enumeration District of the patient on the Scottish incidence date. The easting with the origin based in the Scilly isles."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Constituency",
"dataType": "2",
"sensitive": false,
"description": "Urban/Rural Status Indicator – Derived from the Postcode of the patient on the Scottish incidence date"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old Registry",
"dataType": "2",
"sensitive": false,
"description": "This uniquely identifies which one of the five Scottish regional registries has made the registration. Mandatory for Pre-97 tumours. \n \nCode \tDescription \n0 \tNorth (Inverness) \n2 \tNorth-East (Aberdeen) \n3 \tEast (Dundee) \n4 \tSouth-East (Edinburgh) \n5 \tWest (Glasgow)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Old Alt Case No.",
"dataType": "10",
"sensitive": false,
"description": "Other case ref. numbers used (pre 1997)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Part",
"dataType": "1",
"sensitive": false,
"description": "The local government council area, as defined by the reorganisation of 1 April 1996, where the patient normally resides. This information is derived directly from the patient's postcode of residence."
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Grid Ref Easting",
"dataType": "2",
"sensitive": false,
"description": "Number designated to HB of Residence (1 – 15)"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
},
{
"name": "HISTORICAL DATA",
"columns": [
{
"name": "Parish code",
"dataType": "5",
"sensitive": false,
"description": "Parish area - Derived from the postcode of the patient on the Scottish incidence date"
}
],
"description": "HISTORICAL DATA (1950-1996 registrations only)"
}
],
"tissuesSampleCollection": [
{
"materialType": "None/not available"
}
]
}
Copied to clipboard
Additional information
-
DocumentationDocumentation
-
LanguageEnglish
-
Geographic AreaScotland
Related links
Related resources
Available resource files can be downloaded below.
Requesting access to this data
This is a secure dataset that can only be accessed by researchers from approved organisations.
-
PublisherPublic Health Scotland
-
Contactphs.edris@phs.scot
Synthetic data
Synthetic data is not yet available for this dataset.
Key Details
-
Formal release or publication date31/08/2020
-
Start time period of data covered by this dataset01/01/1981
-
End time period of data covered by this datasetNo information available
-
DocumentationThe registry began in 1958 collecting personal, demographic and diagnosis information (such as site, histology, behaviour, histological confirmation and hospital of diagnosis) from cancer patients. In 1997, a new electronic cancer recording system was launched and at this point the registry was extended to include extra information on tumour stage (for breast, cervical and colorectal cancer), tumour grade and treatment information. A wide variety of geographical data is also included in the dataset including Scottish Index of Multiple Deprivation and Carstairs measures, census output area, NHS Board, Electoral Ward and Parliamentary constituency.
-
Geographic AreaUnited Kingdom,Scotland
-
Landing page
-
LanguageEnglish
-
The dataset typePHYSICAL
-
Update frequencyannual